pyrazines has been researched along with tamoxifen in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fei, P; Kong, AN; Matwyshyn, GA; Rushmore, TH | 1 |
| Ali, IU; Herbert, BS; Kopelovich, L; Passons, CM; Shay, JW; Wright, AC; Wright, WE | 1 |
| Demaria, S; Formenti, SC; Liebes, L; Ng, B; Santori, FR; Vukmanovic, S | 1 |
| Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| De Mesmaeker, P; Deleu, I; Dirix, LY; Prové, A; Rasschaert, M; Sas, L; Tjalma, WA; Trinh, XB; Van Dam, PA; Van de Velde, H; Van Laere, SJ; Vermeulen, PB; Vinken, P; Wojtasik, A | 1 |
| Alexi, X; Boven, E; Kruger, DT; Linn, SC; Opdam, M; Sanders, J; Schuurman, K; van der Noort, V; Voorwerk, L; Zwart, W | 1 |
1 trial(s) available for pyrazines and tamoxifen
| Article | Year |
|---|---|
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Boronic Acids; Bortezomib; Breast Neoplasms; Cytokines; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tamoxifen | 2012 |
6 other study(ies) available for pyrazines and tamoxifen
| Article | Year |
|---|---|
Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents.
Topics: Anticarcinogenic Agents; Blotting, Northern; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Enzyme Induction; Gene Expression Regulation; Genes, Reporter; Glutathione Transferase; Humans; Isothiocyanates; Liver; Pyrazines; Sulfoxides; Tamoxifen; Thiocyanates; Thiones; Thiophenes; Time Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 1996 |
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Disease Progression; DNA, Complementary; Eflornithine; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Li-Fraumeni Syndrome; Oligodeoxyribonucleotides, Antisense; Point Mutation; Pyrazines; Reverse Transcriptase Inhibitors; Tamoxifen; Telomerase; Thiones; Thiophenes; Transformation, Genetic; Tretinoin | 2001 |
Select forms of tumor cell apoptosis induce dendritic cell maturation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; fas Receptor; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Pyrazines; Signal Transduction; Tamoxifen | 2005 |
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2011 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; MAP Kinase Signaling System; MCF-7 Cells; Middle Aged; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyrazines; Receptor, IGF Type 1; Receptors, Estrogen; Tamoxifen | 2020 |